Chemexpress(SH:688131) Shang Hai Zheng Quan Bao·2025-10-09 20:36Core Points - The announcement details the conversion results of the convertible bonds issued by Shanghai Haoyuan Pharmaceutical Co., Ltd. and the changes in share capital as of September 30, 2025 [1][2] Group 1: Convertible Bond Conversion Status - As of September 30, 2025, a total of RMB 464,000 of "Haoyuan Convertible Bonds" has been converted into company shares, resulting in 11,412 shares, which accounts for 0.0054% of the total shares before conversion [2][6] - The amount of "Haoyuan Convertible Bonds" that has not been converted as of September 30, 2025, is RMB 821,886,000, representing 99.94% of the total issuance [2][6] - During the period from July 1, 2025, to September 30, 2025, RMB 414,000 of "Haoyuan Convertible Bonds" was converted into shares, totaling 10,190 shares, which is 0.0048% of the total shares before conversion [2][6] Group 2: Convertible Bond Issuance Overview - The company issued 8,223,500 convertible bonds on November 28, 2024, with a total value of RMB 82,235,000 and a maturity of 6 years [3] - The bonds were listed for trading on December 19, 2024, under the name "Haoyuan Convertible Bonds" with the code "118051" [3] - The initial conversion price was set at RMB 40.73 per share, with adjustments made due to various corporate actions [3][4][5] Group 3: Share Capital Changes - The total share capital of the company was reduced by 47,725 shares on July 4, 2025, due to the cancellation of shares related to performance commitments [7] - The company completed the registration of 648,570 shares from the 2022 restricted stock incentive plan on July 8, 2025, which were then listed for trading [8] - Additional shares from the 2023 restricted stock incentive plan were also registered and listed for trading in subsequent months [8]